The U.S. Food and Drug Administration conducted a public meeting last week about patient-focused drug development for Huntington's and Parkinson's diseases.
The purpose of the meeting was for FDA officials to solicit patient perspectives on the effects of Huntington’s disease and Parkinson’s disease on daily life and gather patient opinions on treatment approaches.
Huntington's and Parkinson's diseases are both neurological conditions, but differ greatly in many respects. The meeting was separated into a morning session to discuss Huntington's disease and an afternoon session to discuss Parkinson's disease.
The meeting took place at the FDA White Oak Campus in Silver Spring, Maryland. It was webcast and is archived and available for viewing at https://collaboration.fda.gov/hpm922/.
